Jack Carter
Director Prelude Therapeutics​
Jack Carter, PhD, is a Director of Biology and Pharmacology at Prelude Therapeutics, where he leads biology drug discovery, pharmacology, and translational research programs. Since joining Prelude in 2019, he has played a key role in advancing innovative therapeutic approaches, including first-in-class targeted protein degraders (TPDs) and antibody degrader conjugates (DACs). Jack completed his postdoctoral training at the Sidney Kimmel Cancer Center at Thomas Jefferson University, where he focused on identifying novel therapeutic targets for patients with drug-resistant prostate cancer. He obtained his PhD in Cell and Molecular Biology from the University of the Sciences in Philadelphia in 2017.
Seminars
Identifying why TPD is the best approach for a target is the first step to becoming the standard of care. In this session, you will explore key factors that determine when a degrader is the best strategy for your target and how to differentiate it from traditional inhibitors. We will cover:
- The unique advantages of degraders: When and why TPD outperforms conventional approaches
- The advantages of a TPD approach versus using inhibition only in regulating BRAF-V600 mutant MAPK pathway signaling in cancer
- Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate robust anticancer activity in pre-clinical models
